Walleye Capital
ABUS icon

Walleye Capital’s Arbutus Biopharma ABUS Stock Holding History

Walleye Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-172,229
Closed -$670K – 2251
2021
Q4 		$670K Sell
172,229
-58,808
-25% -$228K 0.02% 803
2021
Q3 		$991 Buy
+231,037
New +$770K 0.03% 444
2019
Q4 		– Sell
-22,572
Closed -$34K – 1725
2019
Q3 		$34K Buy
+22,572
New +$38.9K ﹤0.01% 1666
2018
Q3 		$128K Buy
+13,593
New +$135K 0.06% 247

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's ABUS Position: Q1 2022 in Review

Walleye Capital sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 172,229 shares — an estimated $670K sold.

Walleye Capital first reported a position in ABUS in Q3 2018 and held it in 4 quarters. The position peaked at $670K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Walleye Capital reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Walleye Capital sold 172,229 Arbutus Biopharma shares in Q1 2022, an estimated $670K.
  • Walleye Capital first reported a position in Arbutus Biopharma in Q3 2018 and held it in 4 quarters.
  • Walleye Capital's Arbutus Biopharma position peaked at $670K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.